The potential reclassification of cannabinoids, particularly at the federal level, is generating considerable anticipation within the market. A shift away from Schedule I status, often viewed as outdated and hindering innovation, could unlock significant avenues for businesses. Reduced regulatory burdens, alongside greater access to banking and inv